What is Hemanext?
Hemanext operates at the intersection of hematology and advanced manufacturing, specializing in the development of proprietary medical devices designed to optimize the processing and long-term storage of red blood cells. By addressing the inherent challenges in blood preservation, the company provides essential technology that enhances the efficacy and safety of transfusion medicine. Their market position is defined by a focus on improving patient outcomes through rigorous engineering and a deep understanding of cellular biology, positioning them as a vital partner for healthcare institutions and blood centers globally.
How much funding has Hemanext raised?
Hemanext has raised a total of $130.9M across 10 funding rounds:
Private Equity
$12.3M
Private Equity
$2.7M
Debt
$2M
Debt
$350K
Series A
$15M
Series B
$18M
Multiple Rounds
$80.6M
Private Equity (2011): $12.3M, investors not publicly disclosed
Private Equity (2017): $2.7M, investors not publicly disclosed
Debt (2018): $2M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Series A (2021): $15M backed by Antaeus Wealth Advisors
Series B (2022): $18M, investors not publicly disclosed
Private Equity (2025): $20M, investors not publicly disclosed
Stock/Share Issuance (2025): $18.9M, investors not publicly disclosed
Stock/Share Issuance (2025): $21.7M, investors not publicly disclosed
Stock/Share Issuance (2025): $20M, investors not publicly disclosed
Key Investors in Hemanext
Antaeus Wealth Advisors
An integrated investment and financial planning firm based in Massachusetts that provides customized financial guidance and strategic capital support for long-term growth.
PPP
Public-Private Partnership
Undisclosed Investor
An institutional partner providing strategic capital to support the scaling and commercialization of advanced medical technology solutions.
What's next for Hemanext?
With the recent influx of capital, Hemanext is well-positioned to accelerate its commercial expansion and deepen its research and development capabilities. The company is expected to focus on scaling its manufacturing operations to meet the growing demand for its specialized blood processing technology. Furthermore, the strategic deployment of these funds will likely support the expansion of their clinical footprint, enabling the firm to navigate the complexities of the medical device regulatory landscape while maintaining its competitive edge in the life sciences sector. As the company matures, the focus will shift toward broader market penetration and the potential integration of its technology into standard blood banking protocols worldwide.
See full Hemanext company page
